12 Results for "

hyperphosphatemia

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "hyperphosphatemia" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-15991
CAS No.: 1234423-95-0
Synonyms: AZD1722; RDX5791
Research Areas:  

Metabolic Disease

Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia .
loading...
    loading...
8
8 Publications Verification
Cat. No.: HY-15991A
CAS No.: 1234365-97-9
Synonyms: AZD1722 hydrochloride; RDX5791 hydrochloride
Research Areas:  

Metabolic Disease

Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N1428C
CAS No.: 3522-50-7
Synonyms: Iron(III) citrate; Zerenex
Ferric citrate (Iron(III) citrate), an orally active iron supplement, is an efficacious phosphate binder. Ferric citratee can be used for iron deficiency anemia and chronic kidney disease (CKD) research .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-13995A
CAS No.: 152751-57-0
Purity:  ≥98.0%
Target:  

FXR

Research Areas:  

Metabolic Disease Endocrinology

Sevelamer hydrochloride is an orally active polymeric phosphate binder and bile acid sequestrant. Sevelamer hydrochloride binds dietary phosphate in the gastrointestinal tract, reducing phosphate absorption and serum phosphorus levels, and reduces urinary phosphate excretion. Sevelamer hydrochloride binds polyanion bile acids, increases bile acid faecal excretion, and reduces total cholesterol and LDL cholesterol levels. Sevelamer hydrochloride can be used for the research of hyperphosphataemia, hyperparathyroidism, chronic renal failure, kidney disease, and type 2 diabetes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-145894
CAS No.: 2227445-31-8
Purity:  98.93%
Target:  

Sodium Channel

Research Areas:  

Metabolic Disease

NaPi2b-IN-2 is a potent inhibitor of sodium-dependent phosphate transporter 2b (SLC34A2, NaPi2b), with an IC50 value of 38 nM against human NaPi2b. NaPi2b-IN-2 reduces intracellular phosphate levels and enhances innate immune gene expression. NaPi2b-IN-2 can be used in research related to hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-171099
CAS No.: 2245949-62-4
Synonyms: LI-2124
Target:  

IPK Superfamily

SC-919 is an orally active IP6K inhibitor, with an IC50 of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-P10909
CAS No.: 2925554-87-4
Synonyms: MBX 2109
Research Areas:  

Endocrinology

Canvuparatide (MBX 2109) is a prodrug for parathyroid hormone (PTH) peptide that releases the bioactive PTH[1-32] peptide agonist that retains a fatty acylated lysine (Lys33) at the C-terminus, thereby extending the halflife of Canvuparatide. Canvuparatide can be used for the symptoms of hypoparathyroidism such as hypocalcemia and hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-174154
CAS No.: 2640089-88-7
Target:  

FGFR

Research Areas:  

Cancer

INCB126503 is an orally activeM, selective FGFR2/3 Inhibitor with IC50 values of 70 nM (FGFR1), 2.1 nM (FGFR2), 1.2 nM (FGFR3), 0.92 nM (FGFR3-V555L), 0.85 nM (FGFR3-V555M) and 64 nM (FGFR4). INCB126503 suppresses FGFR signaling in vivo without causing hyperphosphatemia and shows antitumor efficacy in xenograft models harboring FGFR3 genetic alterations .
loading...
    loading...
Cat. No.: HY-146429
CAS No.: 2227443-66-3
Target:  

Sodium Channel

Research Areas:  

Metabolic Disease

NaPi2b-IN-3 (compound 5) is a potent sodium-dependent transport protein 2b (SLC34A2, NaPi2b) inhibitor with IC50s of 71 nM and 28 nM for human NaPi2b and rat NaPi2b, respectively. NaPi2b-IN-3 can be used for researching hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-142957
CAS No.: 1453116-06-7
Research Areas:  

Others

NaPi2b-IN-1 is a potent and orally active inhibitor of sodium-dependent phosphate transport protein 2b (NaPi2b) with an IC50 of 64 nM. NaPi2b is primarily expressed in the small intestine, lungs, and testes and plays an important role in phosphate homeostasis. NaPi2b-IN-1 has the potential for the research of hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-148479
CAS No.: 851373-13-2
Research Areas:  

Infection

Bixalomer is a phosphate binder. Bixalomer can improve hyperphosphatemia in chronic kidney disease (CKD) rat model. Bixalomer reduces plasma phosphorus level in CKD rat models through binding phosphate in small intestine and reduces phosphate absorption. Bixalomer can be studied in research on hyperphosphatemia .
loading...
    loading...
Cat. No.: HY-159978
CAS No.: 1628848-73-6
EOS789 is an orally active sodium-dependent phosphate transporter inhibitor, with IC50 values of 6.8, 1.5, and 1.7 μM against human NaPi-IIb, PiT-1, PiT-2, respectively; and IC50 values of 3.9, 1.9, and 1.7 μM against rat NaPi-IIb, PiT-1, PiT-2, respectively. EOS789 inhibits intestinal phosphate absorption, increases fecal phosphate excretion, reduces urinary phosphate excretion, and decreases the levels of serum phosphate, FGF23, and adult parathyroid hormone. EOS789 ameliorates ectopic thoracic aortic calcification, renal injury and hyperphosphatemia, and inhibits the expression of fibrosis markers. EOS789 can be used for the research of hyperphosphatemia and chronic kidney disease-mineral and bone disorder (CKD-MBD) .
loading...
    loading...
  • 1